Literature DB >> 15701939

Varicella zoster virus vaccination policies and surveillance strategies in Europe.

A Pinot de Moira1, A Nardone.   

Abstract

The incorporation of varicella zoster virus (ZVV) vaccination in childhood immunisation schedules is becoming an increasingly common option in Europe. The current study forms part of the European Sero-Epidemiology Network 2 (ESEN2) organisational analysis for VZV and describes current passive immunisation policies, as well as current and proposed active immunisation strategies, and existing surveillance systems for diseases caused by the varicella zoster virus in ESEN countries. A questionnaire was compiled and distributed to 23 participating countries. A VZV vaccine is currently licensed in 14 of the 20 participating ESEN countries. Germany is the only country to have incorporated VZV vaccination into its routine childhood immunisation programme. Three further countries currently recommend vaccination of children against VZV and five countries are also considering introducing routine immunisation against VZV for children. However, of the eight countries with or considering introducing childhood VZV immunisation, only six have case-based mandatory notification of varicella, and only two countries have primary care surveillance data available for herpes zoster.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701939

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  12 in total

1.  Presumptive varicella vaccination is warranted in Greek adolescents lacking a history of disease or household exposure.

Authors:  Alexandra Katsafadou; Konstantina Kallergi; George Ferentinos; Theodora Goulioti; Maria Foustoukou; Vassiliki Papaevangelou
Journal:  Eur J Pediatr       Date:  2008-04-05       Impact factor: 3.183

2.  Epidemiological game-theory dynamics of chickenpox vaccination in the USA and Israel.

Authors:  Jingzhou Liu; Beth F Kochin; Yonas I Tekle; Alison P Galvani
Journal:  J R Soc Interface       Date:  2011-06-01       Impact factor: 4.118

Review 3.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

4.  Herpesvirus infections of the central nervous system in immunocompromised patients.

Authors:  Uta Meyding-Lamadé; Cornelia Strank
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

5.  Varicella disease in Beijing in the era of voluntary vaccination, 2007 to 2010.

Authors:  Li Lu; Chengbin Wang; Luodan Suo; Juan Li; Weixiang Liu; Xinghuo Pang; Jane F Seward
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

7.  The epidemiology of varicella in school-aged Greek children before the implementation of universal vaccination.

Authors:  A Katsafadou; G Ferentinos; A Constantopoulos; V Papaevangelou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-16       Impact factor: 3.267

8.  Varicella vaccination in Europe: are we ready for a universal childhood programme?

Authors:  Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer
Journal:  Eur J Pediatr       Date:  2007-03-03       Impact factor: 3.860

9.  Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?

Authors:  G Kafatos; N Andrews; K J McConway; C Anastassopoulou; C Barbara; F De Ory; K Johansen; J Mossong; K Prosenc; R Vranckx; A Nardone; R Pebody; P Farrington
Journal:  Epidemiol Infect       Date:  2014-11-25       Impact factor: 4.434

Review 10.  Similar herpes zoster incidence across Europe: results from a systematic literature review.

Authors:  Sybil Pinchinat; Ana M Cebrián-Cuenca; Hélène Bricout; Robert W Johnson
Journal:  BMC Infect Dis       Date:  2013-04-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.